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ABSTRACT
Effects of Aging and Gender on Vasoreactivity of Coronary Arterioles
Amanda Jo LeBlanc
The purpose of the first study was to determine how age and ovarian hormones
affect flow-induced vasodilation in the coronary microcirculation. Coronary arterioles
were isolated from young, middle-aged, and old control, ovariectomized (OVX) and
ovariectomized + estrogen replaced (OVE) female Fischer-344 rats to assess vasodilation
to increases in flow. L-NAME, a nitric oxide synthase (NOS) inhibitor, was used to
assess NO contribution to flow-induced dilation (FID). FID of coronary arterioles was
impaired with advancing age. Ovariectomy reduced FID in young females only;
however, estrogen-replacement restored or improved FID in all age groups. FID was
reduced after pretreatment with L-NAME in young control and all estrogen-replaced
groups, indicating these dilator responses were mediated through nitric oxide (NO).
Increasing age caused an impairment of FID which corresponds to an age-related loss in
NO-mediated dilation in the coronary microcirculation of female rats. FID in aged
females appears to be impervious to OVX; however, estrogen-replacement improves FID
by ~ 160% versus old control and OVX.
The second study evaluated vasoconstriction to endothelin in coronary arterioles
from young and old male and female Fischer-344 rats. BQ123, an ETa receptor inhibitor,
or BQ788, an ETb receptor inhibitor, was used to assess receptor-specific contributions to
ET-induced vasoconstriction in intact and endothelium-denuded arterioles. Males
exhibited an age-related decline in vasoconstriction to ET in coronary arterioles which is
associated with a decline in ETa receptor mRNA and protein expression. Arterioles from
females demonstrated increased ET-induced vasoconstriction with advancing age, but
this is not associated with an age-related alteration in ETa or ETb receptor mRNA or
protein expression. Aging differentially alters vasoconstriction to ET in coronary
arterioles from males and females, and this may contribute to the gender-related
differences in the development of cardiovascular risk with aging.
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CHAPTER I
INTRODUCTION

Chronic diseases, genetics, and lifestyle choices all interact to influence the
complex process of biological aging. By the year 2030, people 85 years of age and older
will constitute the fastest growing segment of our population (1). Cardiovascular disease
(CVD) remains the leading cause of death in the United States, claiming more lives each
year than the next four leading causes of death combined (111) and the risk for CVD
increases with advancing age (56). Therefore, it is imperative to determine how aging
affects the cardiovascular system in order to contribute to future therapeutic modalities
targeted to CVD.
Cardiac function decreases with advancing age in both humans and animals (2, 3,
42), and can be affected by both structural and functional changes. Although cardiac
output is preserved with age at rest (23, 24, 106), a multitude of age-related changes
occur in the physiological control mechanisms of cardiac function, regardless of gender
(57). These include: increased left ventricular wall thickness, decreased peak heart rate
and stroke volume (58, 107), and a decrease in myocyte number concurrent to an increase
in myocyte cell size (2, 116).
Efficient ejection of blood from the heart occurs when the afterload of the heart
equals that of the vasculature. It has been suggested that the matching of afterloads is
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conserved when young and is preserved with old age at rest only (58). Age-related
cardiac cell-enlargement and subsequent mass increase of the left ventricle contribute to
increases in the load of the heart while the vascular load is augmented as a result of
arterial stiffening that occurs with advancing age (58). Deficiencies in the ability to meet
blood flow demand in the heart or periphery become detrimental when the cardiovascular
system is challenged by activities such as exercise or when transitioning from a seated to
a standing position. Importantly, the inability of the aged coronary vasculature to provide
adequate blood flow in response to increased myocardial demand likely contributes to
compromised cardiac function.
Peak cardiac output, heart rate, and stroke volume all decrease with age (58);
however, the contribution of age-related alterations in regulation of myocardial blood
flow to declining cardiac function remains unclear. The myocardium has a very limited
anaerobic tolerance and is dependent on a constant supply of oxygen from the coronary
circulation (120). Local metabolic feedback, specifically the production of relaxing and
constricting factors, is the primary regulator of coronary blood flow. Due to the high
oxygen (O 2 ) extraction at rest (~75%), increases in cardiac metabolism must be met by
an immediate increase in coronary blood flow or myocardial ischemia can occur. The
age-related increase in the risk for heart failure may be related to a declining coronary
flow reserve that occurs in senescent animals and humans (19, 42). Advancing age has
previously been shown to cause a 43% decrease in maximal coronary reserve in isolated
hearts of male Fischer 344 rats (42), and recently collected data show a similar reduction
in maximal coronary blood flow in senescent female Fischer 344 rats by approximately
24% (Fig 1.1). Therefore, regardless of gender, the myocardium becomes impaired in its
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ability to increase coronary blood flow in response to changes in cardiac metabolism as
age progresses. Aging-induced alterations in coronary vasoreactivity to relaxing or
constricting factors may contribute to the age-related decline in coronary vascular reserve
and increased risk for heart failure.
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Young Female (n = 4)
Old Female (n = 5)

*

*

Coronary Flow
(ml/min/gram)

16

14

12

10

8
Baseline

1e-7

1e-6

1e-5

1e-4

Dea-NONOate [M]
Figure 1.1 The isolated hearts of young and old Fischer 344 females were retrogradely perfused at a
constant pressure of 80 mmHg with oxygenated Krebs-Henseleit buffer at 37°C in a standard Langendorff
preparation and allowed to beat spontaneously. The left ventricle was vented with a small polyethylene
apical drain, and a water-filled balloon made of plastic wrap was inserted into the left ventricle across the
mitral valve through a left atriotomy. The balloon was connected to a fluid-filled pressure transducer by
polyethylene tubing for continuous measurement of left ventricular developed pressure (LVDP). Coronary
flow was continuously measured using an ultrasonic flow probe placed in the aortic perfusion line. Basal
coronary flow was not different between groups when normalized to heart weight. Young females
exhibited greater stimulated increases in coronary flow than old females at higher concentrations of DeaNONOate, an exogenous NO donor. Heart rate was unaffected by increases in coronary flow. * (P<0.05)
Adapted from (110).

Age-induced alterations in vascular function and structure, regardless of gender,
create an environment in which CVD can flourish (57, 58). Endothelium-dependent
vasodilation has been shown to be inversely correlated with aging in large epicardial
coronary arteries (27). Vasodilation of coronary arteries decline with age in response to
noradrenaline (79), adenosine (45), and testosterone (28). Furthermore, isolated coronary
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arteries from aged male rats have shown an exaggerated vasoconstrictor response to
endothelin (51). Therefore, if responsiveness of large coronary arteries to
pharmacological stimuli is impaired with increasing age, aging might alter coronary
resistance vasculature in a similar manner.
Coronary blood flow is meticulously regulated by the release of a combination of
relaxing and constricting factors that help alter blood flow in response to changes in
metabolism. Endothelin (ET) functions as a modulator of basal vascular tone in the heart
and contributes to coronary blood flow during periods of low metabolism (71). The longlasting vasoconstriction caused by ET can redirect coronary blood flow in order to
promote subendocardial perfusion and has been proposed to prevent excessive back flow
from the coronary circulation (71). ET mediates its effects via two distinct G-coupled
protein receptor subtypes. ETa receptors are the major subtype of receptors involved in
the vasoconstrictor response to ET and are localized on the vascular smooth muscle
(VSM) cell (66). ETb receptors located on the endothelial cell mediate vasodilation
through the release of relaxing factors, but can exert vasoconstriction through ETb
receptors located on the smooth muscle (66). Therefore, the net effect of endothelin
depends on the relative distribution and density of each specific subtype of receptor.
Considerable heterogeneity exists in the age-related response to ET in the
vasculature, and depends on which specific vascular bed is being investigated. For
example, a decrease (25), no change (53), or increase (26) in the vasoconstriction to ET
with advancing age has been shown in mesenteric arteries, aorta, and gastrocnemius
arterioles from male rats, respectively. Thus, vasoconstriction to ET varies between
vessels from different vascular beds and between conduit and resistance vessels. This

5
laboratory has previously demonstrated a decrease in vasoconstriction to ET with
advancing age in coronary arterioles from male rats (97). In contrast, in large coronary
arteries from aged male rats, ET-mediated vasoconstriction is increased compared to
arteries from young rats (50, 113). On the other hand, whole-heart evaluations of ETinduced vasoconstriction have shown no age-related changes (34), which suggests an
age-related impairment specific to the microcirculation in male hearts. This decrement in
vasoconstriction to ET may contribute to altered blood flow in the hearts of senescent
male rats (42, 115).
In contrast to the male literature, there are extremely few studies regarding the
age-related response to ET in any vascular bed in females. Large epicardial arteries have
shown a decrease in maximal constriction to ET in senescent females, but this decline in
ET-mediated constriction was associated with an increase in both Big ET and functional
endothelin converting enzyme (ECE) activity, two upstream regulators of endothelin
production (7). In addition, age-related increases in vasoconstrictor responses to 5-HT in
mesenteric arteries (109) and KCl and norepinephrine (NE) in aortas (7) from females
have been reported, along with augmented plasma ET-1 levels in senescent females (7,
11, 122). This suggests that females may exhibit an enhanced vasoconstrictor profile
along with an increase in ET levels as age progresses, and this may contribute to altered
blood flow regulation as age progresses in females.
Much of the current knowledge of aging effects in the coronary vasculature is
confined to large epicardial arteries. Far less is known regarding the effects of age on the
vessels which constitute the majority of coronary vascular resistance (i.e., arterioles <
200 µm in luminal diameter) (16). Although relatively few studies have investigated this
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important area of research, the first found an impairment in endothelium-dependent
vasodilation of septal resistance arteries in middle-aged male rats (18). In addition,
vasoconstrictor responses in coronary resistance arterioles were impaired in aged male
rats (97). Most studies of vasoreactivity have been on resistance vasculature of the
periphery and have shown acetylcholine (ACh)-mediated endothelium-dependent
vasodilation is impaired with advancing age in skeletal resistance arteries of rats (78, 125,
126).
Epidemiological data indicate that the risk for CVD and heart failure increase
with advancing age; however, sexual dimorphism exists in the chronological
development of these risks (55, 102). The risk for CVD begins to increase at
approximately the same age that flow-mediated vasodilation has been shown to decline in
men (12). Women also exhibit this correlation; however, it occurs more than a decade
later (12) and is associated with a decrease in arterial compliance in large arteries (59).
Women experience cardioprotection until menopause, presumably due to estrogen, which
then results in a sex-related delay of the expression of CVD (108). Some of the
cardioprotective effects of estrogen include: a decrease in low-density lipoprotein, an
increase in anti-platelet activity, enhanced levels of anti-oxidants, and the preservation of
endothelium-mediated vasodilation (64, 67). After menopause, impairments in
endothelium-dependent vasodilation of peripheral arteries in women are comparable to
those in aged men (12, 108).
Estrogen can exert its effects in the vasculature by three different methods.
Genomic activation of estrogen receptors is known as the classic pathway. When free
estrogen diffuses into the cell, it binds to the nuclear estrogen receptors (ER) to exert
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conformational changes in the estrogen-ER complex which leads to its activation. This
allows the complex to bind to specific DNA sequences known as estrogen-response
elements to begin transcriptional activity (47). The nongenomic pathway begins with
estrogen binding to the ER on the cell membrane which stimulates the activity of protein
kinases to cause synthesis of target proteins. The protein kinases stimulated by the
membrane ER can also exert transcriptional effects in the nucleus (47); however,
nongenomic action through cell-surface ER receptors is mostly known for a rapid onset
mechanism which causes vasodilation (47), primarily through nitric oxide synthase
(NOS) (14). Lastly, a ligand-independent pathway involves growth factors which
increase the activity of protein kinases which then phosphorylate the unbound ER in the
cytoplasm to cause activation of transcriptional activity in the nucleus (39).
Estrogen has been shown to enhance function of the endothelium in a number of
vascular beds (15, 121, 123, 124). Endothelium-dependent ACh-induced vasodilation in
the peripheral vasculature is preserved or potentiated with chronic estrogen treatment in
young male, ovariectomized (OVX) and sham-operated rats (75, 76, 84, 129). Estrogen
also exerts cardioprotective effects by mediating ER-independent antioxidant action in
the heart (104). Additionally, postmenopausal women display increases in total
antioxidant capacity after undergoing 3 months of hormone replacement therapy (HRT)
(22). In humans, impairment in endothelium-dependent vasodilation of peripheral
conduit arteries is evident after menopause in females (12, 108); however, numerous
studies have shown that chronic estrogen treatment enhances ACh- and/or flow-induced
vasodilation compared to age-matched control males or females (20, 62, 81, 90).
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Recent reports indicate that estrogen exerts vasodilatory effects by binding to the
ER-alpha to increase PI3-kinase activity, resulting in phosphorylation of PKB/Akt and
endothelial nitric oxide synthase (eNOS) (10, 29, 41, 43, 98). Acute estrogen treatment
produces rapid vasodilation in numerous vascular beds (10, 29, 41, 95), and has been
shown to preferentially enhance vasodilation in isolated coronary arteries from women
versus men (15). Recently, chronic estrogen replacement was shown to improve
endothelium-dependent vasodilation in coronary arteries of OVX mice (77). Thus, both
acute and chronic estrogen treatment enhance nitric oxide (NO)-mediated endotheliumdependent vasodilation in young animals; however, more research is needed to examine
how chronic estrogen treatment acts to prevent age-related declines in endothelial
function in coronary arterioles of middle-aged and old animals. Realistically, a decline in
circulating estrogen corresponds to these specific, but understudied, time points of the
female lifespan.
The recent outcomes of the Women’s Health Initiative (WHI) and Heart and
Estrogen/Progestin Replacement Study (HERS), which found an increased risk for
cardiovascular events in those women taking hormone-replacement therapy (HRT)
compared to non-users (49, 87), has prompted investigations into the disparate findings
between these randomized clinical trials and the overwhelming number of animal studies
which have found a beneficial effect of estrogen-replacement (70). Discrepancies in the
timing of hormone-replacement initiation, type and dose of estrogen/progesterone, and
the age and health of women in clinical studies (82) warrant an optimized, more pertinent
animal model that more closely resembles reproductive aging in women. Interestingly,
the Nurse’s Health Study which consisted of over 70,000 asymptomatic women found
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that the risk for major coronary events was lower in women taking hormone therapy
compared to non-users (36-38). It is worthwhile to note that these women initiated
hormone therapy in the perimenopausal period and were free from coronary heart disease
at the time the study began; consequently, these factors may have contributed heavily to
the beneficial results.
Therefore, the overall hypothesis of this proposal is that alterations in vascular
reactivity that occur with age are gender-specific and may contribute to differences in the
risk for CVD in aging men and women (111). An extended, more specific hypothesis is
that the presence of estrogen contributes to the preservation or enhancement of
endothelium-dependent vasoreactivity in coronary arterioles from females throughout
their lifespan. Our knowledge of how age affects the coronary resistance vasculature is
minimal, and information regarding the interaction between age and gender in the
coronary microcirculation is virtually non-existent. Although the rate of aging is
independent of gender, mechanisms that regulate the cardiovascular system during this
time may differ dramatically between men and women. For that reason, the goals of this
project were the following;

1.

To determine whether age and estrogen status alter endothelium-dependent
vasodilator responses in coronary resistance arterioles. Dilation to flow and
Dea-NONOate was assessed in coronary arterioles from young (4 mo), middleaged (14 mo) and old (24 mo) female Fischer-344 rats which had been left
intact, ovariectomized (OVX), or ovariectomized and estrogen-replaced (OVE).
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2.

To determine whether gender and aging alters responsiveness of coronary
resistance arterioles to a vasoconstrictor stimulus. Vasoconstrictor responses
to endothelin were evaluated in intact and denuded coronary arterioles from
young (4 months) and old (24 months) male and female Fischer rats.
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CHAPTER II
ESTROGEN-REPLACEMENT IMPROVES WHILE AGING AND LOSS OF
OVARIAN HORMONES IMPAIR FLOW-INDUCED VASODILATION IN
CORONARY ARTERIOLES

OVERVIEW
Epidemiological data indicate that the risk for cardiovascular disease (CVD)
increases with advancing age; however, the age at which CVD risk increases significantly
is delayed by more than a decade in women compared to men. This cardiac protection,
which women experience until menopause, is presumably due to the presence of ovarian
hormones, in particular estrogen. The purpose of this study was to determine how age
and ovarian hormones affect flow-induced vasodilation in the coronary microcirculation.
Coronary arterioles were isolated from young (6 mo), middle-aged (14 mo), and old (24
mo) control, ovariectomized (OVX) and ovariectomized + estrogen replaced (OVE)
female Fischer-344 rats to assess vasodilation in response to increases in flow (5-60
nl/sec). L-NAME, a nitric oxide synthase (NOS) inhibitor, was used to assess the nitric
oxide (NO) contribution to flow-induced dilation (FID). Advancing age impaired FID of
coronary arterioles (Young: 50 ± 4 vs. Old: 34 ± 6; % relaxation). Ovariectomy reduced
FID in young females only; however, estrogen-replacement restored or improved FID in
all age groups. Pretreatment with L-NAME in young control and all estrogen-replaced
groups reduced FID, indicating that these dilator responses were mediated through NO.
Increasing age caused an impairment of FID which corresponded to an age-related loss in
NO-mediated dilation in the coronary microcirculation of female rats. FID in aged
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females appears to be impervious to OVX; however, estrogen-replacement improved FID
by ~ 160% versus old control and OVX.

INTRODUCTION
Epidemiological data indicate that the risk for cardiovascular disease (CVD) and
heart failure increase with advancing age; however, sexual dimorphism exists in the
chronological development of these risks (55, 102). Although the chronological rate of
aging is independent of gender, mechanisms that regulate the cardiovascular system
across the lifespan may differ dramatically between men and women. The risk for CVD
in men begins to increase at approximately the same age that flow-mediated vasodilation
begins to decline (12). Women also exhibit this age-related correlation in impaired
vasodilation; however, it occurs more than a decade later at the age of menopause (12).
The cardioprotection, which women experience until menopause, presumably is due to
estrogen and results in a sex-related delay of the expression of CVD (108).
Chronic estrogen treatment has been shown to enhance endothelium function in a
number of vascular beds (76, 81, 91) through a well researched pathway involving the
activation of AKT/PKB and subsequent phosphorylation of endothelial nitric oxide
synthase (eNOS) (8, 29, 43, 98, 99). Endothelium-dependent ACh-induced vasodilation
in the peripheral vasculature is preserved or potentiated with chronic estrogen treatment
in male, ovariectomized (OVX) and sham-operated rats (75, 76, 84, 129). In humans,
impairment in endothelium-dependent vasodilation is evident after menopause in females
(12, 108); however, numerous studies have shown that chronic estrogen treatment
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enhances ACh- and/or flow-induced vasodilation in large peripheral arteries of
postmenopausal women (20, 62, 90).
Recently, the Women’s Health Initiative (WHI) (87) and Heart and
Estrogen/Progestin Replacement Study (HERS) (49) found an increased risk for coronary
heart disease and stroke in postmenopausal women taking hormone-replacement therapy
(HRT) compared to non-users. This negative effect of HRT in postmenopausal women in
the randomized clinical trials prompted investigations into the disparate results of animal
studies which have found a beneficial effect of chronic estrogen treatment (6, 75, 129).
Even in humans, postmenopausal women have shown improved endothelium-dependent
function in both small and large coronary arteries after short-term administration of
estrogen (31, 40), which raises questions as to why long-term HRT increases the risk for
coronary heart disease in women after menopause. Discrepancies in the timing of
hormone-replacement initiation, type and dose of estrogen/progesterone, and the age and
health of women in clinical studies (82) warrants an optimized, more pertinent animal
model that more closely resembles reproductive aging in women. The present study
utilizes a unique model, which allows identification of age-related microvascular changes
while incorporating interventions such as the loss of ovarian hormones and/or estrogen
replacement which can realistically occur later in the human lifespan.
The purpose of this study was to determine how advancing age, ovariectomy, and
estrogen-replacement affect NO-mediated FID in the coronary microcirculation.
Increasing age and lack of ovarian hormones were hypothesized to decrease FID in
coronary arterioles. This study specifically investigated mechanisms that could underlie
age- and estrogen-mediated changes in eNOS function.
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METHODS
Animals. Young (4 mo), middle-aged (12 mo) and old (22 mo) female Fischer344 rats were obtained from Harlan (Indianapolis, IN). At the time of arrival, rats were
either sham-operated, ovariectomized (OVX), or ovariectomized + estrogen-replaced
(OVE) and housed for 6 to 8 weeks post-operatively. All procedures were approved by
the Institutional Animal Care and Use Committee at West Virginia University and
conformed to the National Institutes of Health Guide for the Care and Use of Laboratory
Animals (National Research Council, Washington D.C., Revised 1996). Rats were
housed individually at 23º C and were maintained on a 12:12-h light-dark cycle. All rats
were fed a phytoestrogen-free rat chow and water ad libitum. Prior to sacrifice, at least
two complete estrous cycles were monitored in all female rats by daily vaginal smears.
Subsequent analysis of the estrous cycle at time of sacrifice revealed no significant effect
on vascular reactivity, which is consistent with large vessels (100). Plasma samples were
collected at the time of sacrifice and stored at -80ºC until analysis. Plasma estrogen
levels were measured in triplicate by radioimmunoassay (Estradiol, Ultra-Sensitive RIA
Test, Diagnostic Systems).
Surgical Procedures. OVX were performed as described previously (85). OVE
was performed simultaneous to the OVX procedure. Briefly, a scalpel was used to incise
the top layer of skin in close proximity to the scapulae at a length of 1.0–1.5 cm. The
underlying skin was blunt dissected in order to subcutaneously implant two 0.05 mg
17beta-estradiol 60-day slow release pellets (Innovative Research). The outer layer of
skin was then sutured with absorbable suture (Maxon).
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Microvessel Preparation. Six to eight weeks after surgery, rats were anesthetized
(Isoflurane 5%/O 2 balance) and euthanized by removal of the heart. Coronary arterioles
from the left anterior descending artery (LAD) distribution were isolated and cannulated
as described previously (97). Arterioles were cannulated on pipettes matched (within 1%)
for size and resistance, and pressurized at 60 cmH 2 O. Arterioles unable to hold pressure
due to leaks were discarded. Those without leaks were warmed to 37°C, and allowed to
develop spontaneous tone.
Evaluation of vasodilator responses to intraluminal flow. Responses to flow were
used to determine endothelial responsiveness to intraluminal shear stress. Once steady
tone was achieved, arterioles were exposed to graded increases in intraluminal flow at
constant intraluminal pressure by adjusting the height of the fluid reservoirs in equal but
opposite directions, thereby creating a pressure difference across the arterioles without
altering intraluminal pressure within the arterioles (54). Diameter measurements were
determined in response to pressure differences of 2, 4, 10, 20, 40, and 60 cmH 2 O,
corresponding to physiologically significant flow rates from 5 to 60 nl/sec (78).
Responses to Dea-NONOate. Concentration-response relations to cumulative
addition of the nitric oxide donor Dea-NONOate (3x10-9M – 1x10-4M) were determined
in order to differentiate between alterations in endothelial signaling and sensitivity of the
vascular smooth muscle to NO.
Maximal Diameter. At the conclusion of the experiment, the vessels were washed
with Ca2+-free PSS every fifteen minutes for one hour to obtain maximal passive
diameter at 60 cmH 2 O.
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Blockade of Nitric Oxide Synthase and Cyclooxygenase. In a second set of
experiments, the contribution of nitric oxide to flow-induced vasodilation was
reevaluated in the presence of NG-nitro-L-arginine methyl ester (L-NAME; 1x10-5M), a
nonspecific blocker of nitric oxide synthase (NOS). To determine the role of
cyclooxygenase (COX) signaling, indomethacin (1x10-5M) or a combination of both
inhibitors was applied to vessels during exposure to flow.
mRNA Expression. Arterioles were snap frozen and stored at –80°C in 0.5 ml
microcentrifuge tubes. Arterioles were later pulverized in lysate buffer and total RNA
was extracted using an aqueous and ethanol filter isolation method (RNAqueous Isolation
Kit, Ambion). cDNA was made using the High Capacity cDNA Archive Kit (Applied
Biosystems). Real-Time PCR was performed in triplicate, with two no-template control
samples and two reverse transcriptase negative samples (GeneAmp 384 well Optical
Reaction plates). Each reaction well contained the following: 7 ul cDNA, 10 ul Universal
PCR Master Mix, 1 ul 20XTarget Primers and Probe, 2 ul DEPC-treated water. Realtime PCR was performed with TaqMan® probes (Applied Biosystems) specific for rat
Akt-1 (Applied Biosystems). Custom TaqMan(R) probes were designed from the
published sequences for rat eNOS (eNOS primers at exon 8–9 junction: forward, GTG
ACC CTC ACC GAT ACA ACA TAC; reverse, TGT CCG GGT GTC TAG ATC CAT).
PCR was initiated by a 10 min step at 95°C followed by 45 two-step cycles of 15 s at
95°C and then 1 min at 60°C. The fluorescent signal from the probe (FAM-labeled
reporter dye; NFQ labeled-quencher dye) was measured by the ABI prism 7900HT Fast
Real-Time PCR system. The number of cycles required for the fluorescence signal from
each well to reach a fixed threshold is defined as the cycle threshold (Ct). The
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fluorescence signals from 18S mRNA served as controls for the differences in total
cDNA loading in the wells. Levels of target sequence were quantified by calculating the
difference between the Ct for the target sequence and coamplified 18S RNA (∆∆Ct).
One sample with the highest ∆∆Ct value was chosen as a calibrator and assigned a
Relative Quantification (RQ) value of 1.0. All other samples were quantified relative to
the calibrator.
Protein Expression. Segments off of the LAD (≤150 μm D M ; ~1000 μm in
length) were dissected in cold PSS solution (-Albumin) (4 °C). Vessel pieces (n = 4 per
tube) were snap frozen and stored at −80 °C until ready for use. After addition of 20ul
Price-Laemmli lysis buffer, arterioles were solubilized by 3x 2-minute boil, vortex, and
zip-spun. Thereafter, the arterioles were sonicated for 1 minute, and a final 2-minute
boil, vortex, and zip-spin was performed. Protein determination was assessed using
NanoOrange (Molecular Probes). Equal amounts of sample per lane were
electrophoresed on 8% SDS-polyacrylamide gels and transferred to nitrocellulose
membranes. Following blocking, membranes were incubated with primary antibodies for
eNOS (1:1000) (BD Transduction Laboratories), p-AKT (1:500), p-eNOS (1:500), AKT
(1:1000), or β-actin (1:1500) (Cell Signaling Technology) overnight (4 °C). Antibody
binding was assessed by enhanced chemiluminescence (Super Signal, Pierce) following
incubation with secondary anti-rabbit or anti-mouse antibodies as appropriate (1 h).
Densitometric analysis of immunoblot films was performed using NIH ImageJ 1.38x
Analysis Software (National Institutes of Health, Bethesda, MD). Data were normalized
by expressing p-eNOS, p-AKT, eNOS, and AKT values relative to the β-actin loading
control. p-eNOS and p-AKT were expressed relative to the β-actin loading control in
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order to distinguish between absolute differences in protein levels in the absence of
possible age-related changes to either total eNOS or AKT.
Solutions and Chemicals. Albumin was purchased from USB Chemicals
(Cleveland, OH). All other chemicals were purchased from Sigma Chemical (St. Louis,
MO).
Data Analysis. Data are expressed as means ± standard error. Spontaneous tone
was calculated as a percent constriction in relation to maximal diameter as determined by
the following equation:
Spontaneous Tone (%) = [(D M – D T )/D M ] x 100
where D M is the maximal diameter recorded at 60 cmH 2 O and D T is the steady-state
baseline diameter recorded at the same pressure. The vasodilator responses to flow and
Dea-NONOate are expressed as percent relaxation as calculated by the formula:
Relaxation % = [(D S – D B )/(D M – D B )] x 100
where D S is the arteriolar diameter at the respective stage, D B is the diameter recorded
immediately prior to initiation of the flow- or concentration-diameter curves, and D M is
the maximal diameter for the arteriole.
Flow-diameter and concentration-diameter curves were evaluated by repeated
measures ANOVA in order to detect differences within (flow rate or concentration) and
between (experimental groups) factors. A three-way ANOVA was performed to analyze
the slope differences listed in Table 2.3. Pairwise comparisons were made by post-hoc
analysis (Bonferroni’s) when a significant main effect was found. One-way ANOVA
was used to determine differences in BW, HW, HW/BW ratio, uterine weight, estradiol
level, spontaneous tone, and maximal diameter. Significance was defined as P ≤ 0.05.
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RESULTS
Animal Characteristics
Middle-age and old control rats exhibited a greater body weight and heart weight
than young control rats (Table 2.1). The ratio of heart weight to body weight was lower
in middle-age and old control rats compared to young control rats (Table 2.1).
Ovariectomy induced a significant increase in BW and decrease in HW/BW ratio in
young and middle-age females (Table 2.1). Estrogen-replacement caused a decrease in
BW in middle-age and old females compared to age-matched control females, and the
HW/BW ratio was increased in all age-groups vs. control (Table 2.1).Ovariectomy
decreased uterine weight in all age groups compared to control (Table 2.1). Estrogenreplacement increased uterine weight compared to ovariectomized rats in all age groups
(Table 2.1). Concentrations of estradiol were decreased in old females compared to
young females (Table 2.1). Ovariectomy decreased estradiol concentrations in young rats
(Table 2.1). Estrogen-replacement increased circulating estradiol levels significantly in
young OVX rats (Table 2.1).
Vessel Characteristics
Maximal diameter was similar among arterioles from all female groups except
young OVE rats, which exhibited a lower mean diameter (Table 2.2). Spontaneous tone
achieved prior to any intervention was not altered by age or changes in estrogen status.
Treatment with L-NAME increased tone to a similar degree in arterioles from all groups
(Table 2.2). Indomethacin did not significantly alter tone in arterioles from any group
compared to spontaneous tone prior to treatment (Table 2.2). L-NAME + indomethacin
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increased spontaneous tone to a similar degree in coronary arterioles from all groups
except for young control and middle-aged OVX rats (Table 2.2).
Vasodilator responses to flow
Flow-induced dilation in coronary arterioles from old females was impaired
compared to those from young females (Fig 2.1). FID in arterioles from middle-aged
females was intermediate between young and old females.
OVX effect on flow-induced dilation
Coronary arterioles from young females exhibited a significant decline in flowinduced dilation after ovariectomy (Fig 2.2A), whereas dilation of coronary arterioles to
flow in middle-age ovariectomized females was slightly, but not significantly decreased
compared to control females of the same age (Fig 2.2B). Flow-induced dilation of
coronary arterioles was unchanged in old females after ovariectomy (Fig 2.2C)
OVE effect on flow-induced dilation
OVE significantly improved dilation of coronary arterioles to flow in all age
groups compared to OVX (Fig 2.2). In old females, estrogen-replacement augmented
flow-induced dilation to a level significantly greater than that of arterioles from either
control or OVX rats (Fig 2.2C).
NOS inhibition
To determine whether NO contributed to flow-induced dilation in coronary
arterioles, flow was performed in the presence of a nonspecific inhibitor of NOS (LNAME). In control females, only arterioles from young rats exhibited a decrease in flowinduced dilation after L-NAME treatment (Fig 2.3A), indicating a loss of NO
contribution to flow with advancing age. Flow-induced dilation in OVX females of all
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ages was impervious to prior incubation with L-NAME (Fig 2.4). Conversely, blockade
with L-NAME abolished dilation to flow in all OVE females, indicating a reliance on
NO-dependent vasodilation after estrogen replacement, regardless of age (Fig 2.5).
COX inhibition
To demonstrate the limited effect of COX inhibition on flow-induced dilation in
females, the average slope of the dilation to flow before and after treatment with
indomethacin is outlined in Table 2.3 and shown in Appendix A-I. Indomethacin
treatment increased the average slope of the flow-dilation curve in arterioles from old
females, indicating that a COX-dependent constrictor pathway limits flow-induced
dilation in advanced age (Table 2.2). In contrast, flow-induced dilation after treatment
with indomethacin in arterioles from old OVE females was reduced as indicated by a
decrease in the average slope of the flow-dilation curve compared to control conditions
(Table 2.3). In all other females, indomethacin treatment did not alter flow-induced
dilation of coronary arterioles (Table 2.3).
Combined NOS and COX inhibition
In all groups, combined NOS and COX inhibition on FID in coronary arterioles
was similar to NOS inhibition alone (Appendix A-I).
Vasodilator responses to DEA-NONOate
To determine whether the age-related impairment of vasodilation in coronary
arterioles was due to a decrease in smooth muscle responsiveness to NO, vasodilation to
DEA-NONOate was measured. DEA-NONOate elicited similar dilation in coronary
arterioles from young, middle-aged, and old females (Fig 2.6A). In addition, neither
OVX nor OVE altered dilation of coronary arterioles to DEA-NONOate compared to
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dilation of arterioles from age-matched control rats (Fig 2.6 B,C,D). Coronary arterioles
from middle-aged OVE rats exhibited greater dilation to DEA-NONOate than those from
MA OVX rats (IC 50 : MA OVX = 2.31x10-6 M, MA OVE = 7.01x10-7 M; P ≤ 0.05).
AKT and eNOS mRNA levels
In coronary arterioles from control females, AKT mRNA expression declined
with age (Fig 2.7A). OVX decreased (vs. control) while OVE increased (vs. OVX) AKT
mRNA in coronary arterioles from both young and middle-age females (Fig 2.7A). In
coronary arterioles from middle-aged and old OVX rats, estrogen-replacement increased
AKT mRNA expression to levels greater than those of arterioles from age-matched
control rats (Fig 2.7A).
Similar to AKT mRNA, advancing age also caused a decrease in eNOS mRNA in
coronary arterioles from middle-age and old control females compared to arterioles from
young females; however, OVX did not alter eNOS mRNA in any age group (Fig 2.7B).
OVE upregulated eNOS mRNA in both young and middle-age females compared to
control and OVX (Fig 2.7B). Surprisingly, OVE did not alter eNOS mRNA in coronary
arterioles from old rats (Fig 2.7B).
p-eNOS, p-AKT, eNOS, and AKT protein levels
Basal p-AKT was undectable in coronary arterioles from all groups. Total AKT
was similar in coronary arterioles from all groups (Fig 2.8 and Appendix N-Q). There
was a 40% age-related decline in basal p-eNOS protein with advancing age (YC:
0.63±0.10, OC: 0.38±0.05; arbitrary units) (Fig 2.8A); however, no age-related
differences were found in total eNOS protein levels (Fig 2.8A and Appendix J).
Coronary arterioles from young females exhibited no changes in p-eNOS or total eNOS
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protein after OVX or OVE (Fig 2.8B and Appendix K). There was a 93% increase in peNOS after OVE treatment in middle-age females (MC: 0.54±0.08, M OVE: 1.04±0.25;
arbitrary units) (Fig 2.8C), but no changes were found in total eNOS after treatment (Fig
2.8C and Appendix L). After OVE, coronary arterioles from old females exhibited a
49% increase in p-eNOS (OC: 0.35±0.04, O OVE: 0.52±0.02; arbitrary units) and a 67%
increase in total eNOS protein (OC: 0.48±0.05, O OVE: 0.80±0.10; arbitrary units) (Fig
2.8D).
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Young

MA

Old

Young

MA

Old

Young

MA

Old

Control

Control

Control

OVX

OVX

OVX

OVE

OVE

OVE

210±3

262±4*

304±4*

241±5

(24)

(17)

(20)

(17)

(21)

(13)

(12)

595±11

699±14*

760±17*

623±12

700±16

761±18

622±21

2.83±0.03

2.67±0.04*

2.52±0.06*

2.60±0.04

Uterine Weight (mg)

507±41

628±32*

537±49

118±13

Estradiol (pg/ml)

66±16

Body
Weight (BW) (g)
(n)

†

278±6

†

298±5

212±5

#

249±5

‡#

281±7

(14)

‡

(9)

Heart
Weight (HW) (mg)

HW/BW (mg/g)

< 20

< 20

†

†

2.52±0.04

194±20

†

†

2.56±0.06

292±48

†

2.97±0.07

233±22

744±15

‡#

‡#

‡

2.99±0.04

491±33

‡#

‡#

854±43

‡#

3.04±0.12

721±64

‡#

#

40±8

Table 2.1. Animal characteristics of young, middle-aged, and old control, OVX, and OVE rats. Values are means ± SE. * Indicates significant age-related
difference vs. young control, † Indicates significant OVX effect vs. age-matched control, ‡ Indicates significant OVE effect vs. age-matched control, # Indicates
significant OVE effect vs. age-matched OVX (P ≤ 0.05).
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Young

MA

Old

Young

MA

Old

Young

MA

Old

Control

Control

Control

OVX

OVX

OVX

OVE

OVE

OVE

136±4

138±5

143±5

131±5

142±5

144±5

141±4

136±5

(31)

(23)

(33)

(28)

(31)

(31)

(23)

(29)

(29)

43±3

49±3

46±3

49±4

51±3

52±3

45±5

52±3

45±3

(31)

(23)

(33)

(28)

(31)

(31)

(23)

(29)

(29)

42±3

49±4

46±4

49±4

45±3

50±4

40±6

50±3

42±4

(14)

(14)

(14)

(16)

(15)

(13)

(14)

(16)

(15)

54±5

59±3

67±5

62±7

70±4

68±3

60±8

63±5

63±6

(14)

(14)

(14)

(16)

(15)

(13)

(14)

(16)

(15)

39±5

37±3

34±6

30±5

42±4

34±7

30±3

46±5

37±4

(5)

(5)

(8)

(8)

(8)

(5)

(6)

(7)

(9)

36±4

35±3

39±5

39±5

48±5

43±4

33±4

53±4

46±6

(5)

(5)

(8)

(8)

(8)

(5)

(6)

(7)

(9)

39±5

39±3

34±7

30±5

41±5

35±4

31±3

46±6

36±4

(5)

(6)

(7)

(8)

(7)

(7)

(7)

(6)

(11)

52±5

60±6

62±9

68±3

53±5

74±4

65±6

(6)

(7)

(8)

(7)

(7)

(6)

(11)

Maximum
Diameter (µm)

Spontaneous Tone (%)

Pre-LNAME

Post- LNAME

Pre-INDO

Post- INDO

Pre-LNAME + INDO

Post- LNAME +
INDO

50±5
(5)

53±9
(7)

123±5

‡

Table 2.2. Vessel characteristics of isolated coronary arterioles in young, middle-aged, and old control, OVX, and OVE rats. Values are means ± SE. *
Indicates significant age-related difference vs. young control, † Indicates significant OVX effect vs. age-matched control, ‡ Indicates significant OVE effect vs.
age-matched control, # Indicates significant OVE effect vs. age-matched OVX , Indicates significant inhibitor effect vs. control (P ≤ 0.05).
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Young

MA

Old

Young

MA

Old

Young

MA

Old

Control

Control

Control

OVX

OVX

OVX

OVE

OVE

OVE

0.98±0.09
(14)

0.92±0.20
(14)

0.62±0.12
(14)

0.62±0.08
(16)

0.53±0.13
(15)

0.62±0.21
(13)

0.94±0.07
(14)

1.02±0.12
(16)

1.19±0.12
(15)

0.87±0.16

0.60±0.13

1.08±0.30

0.67±0.14

0.58±0.18

0.79±0.13

0.96±0.23

0.77±0.24

0.65±0.12

(5)

(5)

(8)

(8)

(8)

(5)

(6)

(7)

(9)

Mean Slope (β) of
Flow-induced Dilation
Post-INDO

Table 2.3. Mean slope (β) of flow-induced dilation before and after treatment with indomethacin (1x10-5 M), a COX inhibitor, in isolated coronary arterioles in
young, middle-aged, and old control, OVX, and OVE rats. Values are means ± SE. Indicates significant inhibitor effect vs. control (P ≤ 0.05).
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Figure 2.1. Flow-induced dilation in young, middle-aged and old control females. Old females have less
dilation to flow than young females. Values are means ± SE. * Indicates significant age-related difference
vs. young control (P ≤ 0.05).

28

A
80

Young Control (n = 13)
Young OVX (n = 11)
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% Relaxation

60

† #

40

20

0

0

B

20

30

40

50

60

Flow (nl/sec)
80

Middle-Aged Control (n = 11)
Middle-Aged OVX (n = 16)
Middle-Aged OVE (n = 13)

60

% Relaxation

10

#

40

20

0

0

C

20

30

40

50

60

Flow (nl/sec)
80

Old Control (n = 15)
Old OVX (n = 9)
Old OVE (n = 10)

60

% Relaxation

10

‡ #

40

20

0

0

10

20

30

40

50

60

Flow (nl/sec)

Figure 2.2. A) Flow-induced dilation is decreased after OVX in young females, but restored to control
levels after OVE. B) OVX does not decrease FID in middle-age females, but OVE increases FID
compared to OVX. C) OVE increases FID in old females. Values are means ± SE. † Indicates significant
OVX effect vs. control, ‡ Indicates significant OVE effect vs. control, # Indicates significant OVE effect
vs. OVX (P ≤ 0.05).
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Figure 2.3. Flow-induced dilation in the presence and absence of L-NAME (1x10-5 M), a NOS inhibitor, in
young, middle-age, and old control females. FID in young females is reduced after pretreatment with LNAME (A). Values are means ± SE. Indicates significant inhibitor effect vs. control (P ≤ 0.05).
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Figure 2.4. Flow-induced dilation in the presence and absence of L-NAME (1x10-5 M), a NOS inhibitor,
in young, middle-age, and old OVX females. L-NAME did not alter FID in OVX females. Values are
means ± SE.
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Figure 2.5. Flow-induced dilation in the presence and absence of L-NAME (1x10-5 M), a NOS inhibitor,
in young, middle-age, and old OVE females. FID is decreased after pretreatment with L-NAME in all age
groups. Values are means ± SE. Indicates significant inhibitor effect vs. control (P ≤ 0.05).
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Figure 2.6. Concentration-response curves to Dea-NONOate, an exogenous NO donor. Dilation to DeaNONOate did not change with advancing age or after treatment compared to control. Sensitivity (IC 50
values) for Dea-NONOate in coronary arterioles from middle-aged OVE was greater than those from
middle-aged OVX (MA OVX: 2.31x10-6 M, MA OVE 7.01x10-7 M). Values are means ± SE. # Indicates
significant OVE effect vs. age-matched OVX (P ≤ 0.05).
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Figure 2.7. mRNA RQ values for AKT (A) and eNOS (B) for all female groups (n ≥ 8 per group). Values are means ± SE. * Indicates significant age-related
difference vs. young control, † Indicates significant OVX effect vs. age-matched control, ‡ Indicates significant OVE effect vs. age-matched control, # Indicates
significant OVE effect vs. age-matched OVX (P ≤ 0.05).
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Figure 2.8. Western blot analysis of p-eNOS relative to β-actin loading control (bar graphs). There was an
age-dependent decrease in p-eNOS protein (A) (YC: 8, MC: 4, OC: 7; n values). There was no OVX or
OVE effect in p-eNOS in arterioles from young females (B) (YC: 14, YO: 6, YE: 6; n values). Middle-age
females exhibited more p-eNOS protein after OVE compared to control (C) (MC: 6, MO: 7, ME: 5; n
values). Old females upregulated p-eNOS and total eNOS protein after OVE (D) (OC: 10, OO: 3, OE: 3; n
values). Values are means ± SE. * Indicates significant age-related difference vs. young control, ‡
Indicates significant OVE effect vs. age-matched control (P ≤ 0.05).
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DISCUSSION
Although there are numerous reports in the literature detailing the beneficial
influence of OVE on the vasculature in young animals (10, 29, 41, 95), there are
relatively few studies examining the influence of exogenous estrogen on the aged
vasculature. Therefore, the foremost finding of this study is that FID in coronary
arterioles of old OVE female rats was improved above FID in arterioles from old control
and old OVX rats (Fig 2.2C), indicating a favorable coronary microvascular response to
estrogen-replacement following ovariectomy in this aged population. This encouraging
improvement in endothelial function is accompanied by an increase in both p-eNOS and
total eNOS protein after estrogen-replacement (Fig 2.8D). Congruent with the
hypothesis, coronary arterioles from young females exhibited a decline in FID after
ovariectomy (Fig 2.2A) and OVE restored dilation to flow in coronary arterioles from
young and middle-age female rats compared to OVX alone (Fig 2.2 A,B). As
hypothesized, FID was decreased with advancing age in control females due to the loss of
NO-mediated dilation (Fig 2.1, 2.3).
The novelty of this study is the examination of the coronary microcirculation
throughout the lifespan of female rats and the investigation of the effects of estrogen
status in young, middle-aged, and old rats. Endothelium-dependent vasodilation has been
shown to be inversely correlated with aging in large epicardial coronary arteries (27).
Vasodilation of coronary arteries in response to noradrenaline (79), adenosine (45), and
testosterone (28) declines with age. Additionally, impaired endothelium-dependent
vasodilation of septal arteries (~200 μm) in middle-aged male rats has been reported (18).
However, much of the current literature regarding aging effects in the coronary
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vasculature is confined to studies of larger resistance arteries from males. The present
study illustrates an age-related impairment in endothelium-dependent dilation in coronary
arterioles from female rats (Fig 2.1), which is associated with a decrease in p-eNOS
protein (Fig 2.8a) and the loss of NO-dependent dilation (Fig 2.3). These findings extend
previous studies showing that FID in females decreases with advancing age in brachial
arteries (12, 83) and mesenteric arteries (4).
In the present study, young females were the only age group where OVX
decreased FID (Fig 2.2A). Blockade with L-NAME indicated that OVX reduced FID
through a loss of NO-mediated signaling (Fig 2.4A). In the cerebral microcirculation,
OVX has been shown to completely abolish endothelium-dependent dilation due to
upregulation of caveolin-1, a negative regulator of eNOS (84). In all OVX groups, FID
was NOS- and COX-independent as indicated by the lack of L-NAME and/or
indomethacin effect (Fig 2.4 and Appendix D-F). Xu, et al. (127) found that cerebral
arterioles from OVX rats lose NO contribution compared to those from control rats, but
are more sensitive to a K Ca 2+ channel blocker, suggesting a conversion to hyperpolarizing
factor dependency in the absence of estrogen. Golding and Kepler have shown that in
cerebral arteries of control female rats, endothelial derived hyperpolarizing factor
(EDHF)-mediated dilations are negligible but can be enhanced after OVX (32).
Therefore, it seems plausible that a conversion from NO-dependency to EDHF
dependency of FID occurs after OVX in all age groups, especially young females.
Estrogen-replacement after OVX enhanced FID of coronary arterioles from all
age groups (Fig 2.2). OVE restored FID in coronary arterioles from young and middleaged females to the level seen in control (Fig 2.2 A,B), while in old females OVE
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increased FID of coronary arterioles to a level significantly greater than responses in
coronary arterioles from old control and OVX (Fig 2.2C). This enhanced FID in
coronary arterioles from old OVE females corresponds to increases in NO-signaling, peNOS and total eNOS protein (Fig 2.8D). Restoration of NO-dependent dilation to
control levels after OVE has been observed previously in cerebral arteries (84), and was
primarily mediated through an increase in eNOS protein expression. Similarly, in the
coronary microcirculation of guinea pigs, estrogen-replacement following OVX
increased dilator sensitivity through an enhancement of endothelium-dependent NO
production (112). Additionally, multiple human studies have shown that HRT in
postmenopausal women improves FID in peripheral conduit arteries (20, 62, 90). These
data now show that estrogen supplementation also improves NO-mediated vasodilation in
the coronary resistance vasculature even at an advanced age.
The age-related impairment of FID in old females is presumably due to a loss of
NO-mediated dilation, as demonstrated by an absence of L-NAME inhibition of FID (Fig
2.3 A,C). Previous work in mesenteric arterioles has demonstrated that advancing age
causes a decrease in shear stress-induced production of p-eNOS and NO (105). In this
study, the loss of NO-mediated FID with advancing age coincides with an apparent
increase in COX-dependent vasoconstriction, indicated by a significant increase in FID
after pretreatment with indomethacin of coronary arterioles from old females (Appendix
C). Stewart et al. have established that a decline in circulating estrogen (6) and
advancing age (103) enhances prostaglandin H synthase (PGHS)-2-dependent
vasoconstriction in mesenteric arteries while simultaneously decreasing NO-dependent
vasodilation. Likewise, an increase in circulating estrogen improved vasodilation in aged
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rats by decreasing both PGHS-dependent constriction in mesenteric arteries (6) and
EDHF-mediated dilation in cerebral arteries (32). In the present study, inhibition with
indomethacin caused a reduction in the slope of FID in arterioles from old OVE females
compared to pretreatment FID in old OVE rats (Table 2.3). This indicates that estrogenreplacement reduced COX-dependent vasoconstriction which was present in FID of
coronary arterioles from old control females. In the present study, L-NAME abolished
FID in coronary arterioles from OVE rats in all age groups (Fig 2.5) indicating
substantial NO-dependence of FID in estrogen-replaced rats. The precise mechanism
whereby estrogen improves NO-mediated vasodilation has not been demonstrated but
may be due to estrogen effects on eNOS expression or mechanisms that regulate eNOS
function, such as the PI3-kinase/AKT pathway (10, 29, 43).
In endothelial cells, acute administration of estrogen causes phosphorylation of
AKT within one minute, followed closely by phosphorylation of eNOS (29). In the
present study, in the absence of acute stimulation, p-AKT was undetectable in pooled
coronary arteriole samples. Bhuiyan, et al. found no changes in p-AKT or total AKT
protein after OVX in left ventricular tissue from female Wistar rats (8). Although there
are reports in the literature detailing molecular evidence that AKT is responsive to the
presence of estrogen (29, 48, 99), these studies utilize an acute exposure to estrogen
rather than the chronic estrogen treatment used in the present study. Although it would
seem reasonable that chronic administration of estrogen would lead to an increase in
mRNA and protein of AKT, while a lack of circulating estrogen (with advancing age or
with OVX) would reduce AKT expression, these results indicate that chronic alterations
in circulating estrogen levels alter AKT mRNA expression rather than AKT protein
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expression. Thus, the current findings suggest estradiol regulation of NO-signaling
occurs at other sites of regulation, possibly through effects on eNOS expression (Fig
2.8A) or upstream signaling at the level of the cell membrane.
Whereas AKT has been largely unstudied after chronic estrogen replacement,
there is an abundance of reports illustrating both the presence (69, 84, 86, 93) and
absence (8, 52, 80) of estrogenic modulation of eNOS expression in various vascular
beds. The present data show that the removal of estrogen (OVX) does not alter eNOS
mRNA expression. In contrast, eNOS mRNA is upregulated by OVE in coronary
arterioles from young and middle-aged females (Fig 2.7B). OVE has also been reported
to increase eNOS mRNA in the thoracic aorta (86). Similar to findings reported in
cerebral microvessels (52), mesenteric arteries (80), and left ventricular tissue (8); neither
OVX nor OVE altered total eNOS protein in coronary arterioles from young and middleaged rats (Appendix K,L). In contrast to the present results obtained in young rats, both
p-eNOS and total eNOS protein were increased in arterioles from old females after
estrogen-replacement (compared to control, Fig 2.8D). However, OVX and OVE did not
alter eNOS mRNA expression in coronary arterioles from old rats. Numerous posttranslational modifications can influence the activity of eNOS, and may contribute to the
increase in NO-mediated vasodilation in middle-aged and old females, including
decreases in ubiquitination, methylation, or receptor degradation after estrogenreplacement. Considered together, these data suggest that the age-related decrease in peNOS protein (Fig 2.8A) and NO-mediated dilation to flow that occurs in coronary
arterioles can be ameloriated by upregulation of post-translational mechanisms that
enhance function of eNOS protein in old female rats supplemented with estrogen.
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Collectively, a beneficial effect of estrogen-replacement following ovariectomy
was demonstrated on endothelial function in the coronary microcirculation of aged
female rats; however, recent randomized, placebo-controlled trials in older women
receiving HRT have not shown any benefit in either primary prevention or secondary
prevention of coronary heart disease and/or myocardial infarction (49, 87). One logical
explanation for the discrepancy between studies may be attributed to differences in the
timing of initiation of estrogen-replacement following ovariectomy (or
hysterectomy/menopause in women). The WHI initiated HRT at a mean age of 63 years,
placing the women at least 10 years after menopause (87). There are many factors that
could influence the overall outcome of HRT in the decade gap between menopause and
initiation of HRT, including changes in body composition, overall activity levels, and the
health of the vasculature that were not taken into account in the clinical trials. These
factors may have contributed to the increased risk for cardiovascular events in
postmenopausal women even after HRT. The Nurse’s Health Study, an observational
study consisting of 70,000 asymptomatic women, initiated HRT in the perimenopausal
period and showed a lower incidence of cardiovascular events and all-cause mortality
compared to non-HRT-users (36-38). In fact, a recent reanalysis of the WHI results
found that women who initiated HRT closer to menopause tended to have a lower risk of
overall coronary heart disease (88). Perhaps the simultaneous estrogen-replacement and
ovariectomy in the present study resulted in the maintenance of healthy endothelial
function, mitigating the progression of deleterious cardiovascular alterations, such as
atherosclerosis, known to flourish in postmenopausal women (35). Animal studies (117),
the Nurse’s Health Study (36-38), and the Cardiovascular Health Study (46) all suggest
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that favorable effects of estrogen may be limited to those in whom atherosclerosis has not
yet developed.
In the present study, increases in body weight with advancing age and after
ovariectomy were associated with a decrease in endothelium-dependent vasodilation in
coronary arterioles. Previous research in brachial arteries have shown that in an
overweight population, endothelial function is most impaired in the highest tertile of
body weight compared to the lowest (5), while postmenopausal women with higher
visceral body fat exhibit lower flow-mediated velocity when compared with leaner
subjects (65). In the coronary circulation, an increase in body weight has been shown to
be independently associated with abnormal coronary circulatory function that progresses
from impairment in vascular vasomotion in overweight individuals to an impairment of
total vasodilator capacity in obese individuals (92). Fulop et al. recently found that in
normotensive subjects, dilations to bradykinin and sodium nitroprusside, an NO donor,
were both decreased in isolated pressurized coronary arterioles from obese humans (30).
Therefore, a possible interaction may exist between a change in body fat mass and
endothelial function that may be superimposed upon alterations that occur with
advancing age and hormonal state.
The major finding from this study is that estrogen-replacement following
ovariectomy restores or enhances FID in coronary arterioles from all ages of female
Fischer-344 rats. Not only does estrogen-replacement improve FID in coronary arterioles
from aged females compared to arterioles from old control and OVX females, it also
eliminates age-related impairments in FID in coronary arterioles by upregulating the
contribution of NO to dilation, p-eNOS and total eNOS protein. These observations are
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in stark contradiction to the recent negative outcomes of both the WHI and HERS studies
but answers key questions as to the functional integrity of the coronary microvasculature
in aged females after estrogen-replacement. Taken together, the present study suggests
that the timing of HRT and the overall health of the vasculature are vital components to
positive effects of estrogen-replacement in postmenopausal women.
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CHAPTER III
AGING AND GENDER EFFECTS ON VASOCONSTRICTION TO ENDOTHELIN IN
CORONARY ARTERIOLES

OVERVIEW
Epidemiological data indicate that the risk for CVD and heart failure increase
with advancing age; however, sexual dimorphism affects the chronological development
of these risks (12). Coronary blood flow is regulated by the release of a combination of
vasodilators and vasoconstrictors, and altered coronary vasoconstrictor responses in both
males and females may contribute to the decline in coronary function and increased risk
for CVD that occurs with advancing age. Coronary arterioles were isolated from young
(6 mo) and old (24 mo) male and female Fischer-344 rats to assess vasoconstriction
responses to endothelin (ET) (1x10-11 to 3x10-8 M). An ETa receptor inhibitor, BQ123
(1x10-6 M), or an ETb receptor inhibitor, BQ788 (3x10-8 M), was used to assess specific
receptor contribution to ET-induced vasoconstriction in intact and endothelium-denuded
arterioles. In coronary arterioles from males, ET-induced vasoconstriction declined with
advancing age and was accompanied by a decrease in ETa receptor mRNA and protein
expression. In contrast, ET-induced vasoconstriction increased in coronary arterioles
from females with advancing age and neither ETa nor ETb receptor mRNA or protein
expression changed with age. Thus, aging-induced alterations in responsiveness of the
coronary resistance vasculature are gender-specific, possibly contributing to the sexual
dimorphism in the risk of CVD with advancing age.
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INTRODUCTION
Overwhelming evidence demonstrates that gender plays an important role in the
development of cardiovascular disease with advancing age. Specifically, endothelial
dysfunction occurs more than a decade later in women compared to men. Recent data
(60, 61) suggest that endothelium-dependent dilation declines with age in coronary
arterioles from both males and female rats; however, the underlying mechanisms that
contribute to the decline in endothelial function are gender-specific. In contrast, little is
known with regard to sex-specific adaptations of vasoconstrictor responses that occur in
the coronary vasculature with advancing age. Previous work indicates that endothelial
modulation of vasoconstrictor responses increased with age in coronary arterioles from
male rats (96); however, because estrogen exerts a potent vasodilatory influence in the
vasculature, it seems plausible that a decline in circulating estrogen that occurs with old
age in females might lead to an increase in vasoconstrictor responses.
Advancing age causes a decrease in cardiac function (3) and reduces maximal and
submaximal coronary blood flow in aged rats (42) and humans (19). Endothelin (ET) is a
21-amino acid vasoconstrictor peptide that is released from the coronary vasculature in
response to a stimulus from cardiac myocytes (71), causing a potent and long-lasting
coronary vasoconstriction (118).

Others have previously shown an altered response to

ET in the aorta (7) and in large coronary arteries (51) with advancing age. Furthermore, a
decrease in ET-induced vasoconstriction in coronary resistance arterioles occurred with
advancing age in male rats (97); however, it remains to be determined whether age alters
ET-mediated responses of coronary arterioles from females as it does in males.
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ET has been shown to be involved in determining basal coronary arteriolar tone,
and a reduction in its presence contributes to regulation of coronary blood flow during
increased metabolism (72). The long-lasting vasoconstriction caused by ET can redirect
coronary blood flow in order to promote subendocardial perfusion, and has been
proposed to prevent excessive back flow from the coronary circulation (71). Endothelin
mediates its effects via two distinct G-coupled protein receptor subtypes. ETa receptors
are the major subtype of receptors involved in the vasoconstrictor response to ET and are
localized on the vascular smooth muscle (VSM) cell (66). ETb receptors located on the
endothelial cell mediate vasodilation through the release of relaxing factors, but can exert
vasoconstriction through ETb receptors located on the smooth muscle (66). Therefore,
the net effect of endothelin depends on the relative distribution and density of each
specific subtype of receptor. This laboratory has previously shown that advancing age
decreases vasoconstriction to ET in coronary arterioles from males (97); however, the
precise mechanisms of the reduced responsiveness to ET seen in coronary arterioles have
not been identified, nor has the effect of age on responsiveness to ET been investigated in
females. The effects of age on ET signaling through specific receptor subtypes have not
been investigated in the coronary circulation of males or females. Therefore, the goals of
this study were to 1) determine whether age-induced alterations in vasoconstrictor
responses of coronary arterioles are gender specific, and 2) determine the effects of age
on signaling through ETa and ETb receptors in coronary arterioles from male and female
rats.

METHODS
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Animals
Young (6 mo; n = 54) and old (24 mo; n = 48) male and young (n = 35) and old
(n = 34) female Fischer-344 rats were obtained from Harlan (Indianapolis, IN). All
procedures were approved by the Institutional Animal Care and Use Committee at West
Virginia University and conformed to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals (National Research Council, Washington D.C.,
Revised 1996). Rats were housed individually at 23º C and were maintained on a 12:12h light-dark cycle. All rats were fed standard rat chow and water ad libitum.
Microvessel Preparation
Rats were anesthetized (isoflurane 5%/O 2 balance) and euthanized by removal of
the heart. The heart was rinsed and placed in cold (4°C) physiological saline solution
(PSS) containing 145.0 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl 2 , 1.17 mM MgSO 4 , 1.2
mM NaH 2 PO 4 , 5.0 mM glucose, 2.0 mM pyruvate, 0.02 mM EDTA, 3.0 mM MOPS
buffer, and 1 g/100 ml BSA, pH 7.4. Resistance vessels (<150 μm) from the left anterior
descending artery distribution were dissected free under a dissection microscope
(Olympus SVH10) and removed from the surrounding cardiac tissue. The arterioles were
transferred to a Lucite chamber containing PSS equilibrated with room air. The ends of
the arteriole were cannulated with a micropipette and secured with nylon suture

The

chamber containing the cannulated arteriole was then place on an inverted microscope
(Olympus IX70) equipped with a video camera and micrometer (Panasonic BP310; Texas
A&M Cardiovascular Research Institute) to measure the intraluminal diameter. The
coronary arterioles were then pressurized at 60 cm H 2 O with two hydrostatic columns.
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Arterioles unable to hold pressure due to leaks or branches were discarded. Those
without leaks were warmed to 37°C and allowed to develop spontaneous tone.
Responses to Endothelin
To determine whether aging alters sensitivity and/or maximal responses to ET, a
concentration-response curve to ET was generated. Changes in diameter were measured
in response to cumulative additions of ET (1x10-11M – 3x10-8M; 5-minute stages) to the
vessel bath.
ET Receptor Blockade
To determine the contribution of ET receptor subtypes in the age-related
alteration of ET-mediated constriction, the ET concentration-response was evaluated in
the presence of either a specific ET A receptor (BQ-123, 1x10-6 M) or ET B receptor (BQ788, 3x10-8 M) antagonist (73).
Removal of the Endothelium
To determine the role of the endothelium in modulating ET-induced
vasoconstriction, the endothelium was removed, and the above experiments were
repeated. The endothelium was denuded by passing approximately 12 cc of air through
the vessel lumen. Lack of vasodilation to 3x10-4M ACh confirmed removal of the
endothelium.
Passive Pressure Responses
In order to determine maximal diameter and passive responses to increasing
pressure, the solution in the bath and pressure lines was replaced with calcium-free PSS
containing 2.0 mM EDTA. Arterioles were washed every 15 minutes and allowed to
completely relax at 60 cm H 2 O for 45 minutes. Maximal diameter at 60 cm H 2 O was
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recorded, and then the passive pressure response was determined by lowering the
pressure reservoirs to 0 cm H 2 O, and recording diameters as pressure was increased
incrementally by 15 cm H 2 O to 135 cm H 2 O. This procedure was performed in arterioles
from females only, as a similar experiment has already been performed in arterioles from
males (97).
Determination of ETa and ETb receptor mRNA
Arterioles were snap frozen and stored at –80°C in 0.5 ml microcentrifuge tubes.
Arterioles were later pulverized in lysate buffer and total RNA was extracted using an
aqueous and ethanol filter isolation method (RNAqueous Isolation Kit, Ambion). cDNA
was made using the High Capacity CDNA Archive Kit (Applied Biosystems). RealTime PCR was performed in triplicate, with two no-template control samples and two
reverse transcriptase negative samples, using GeneAmp 384 well Optical Reaction
plates. Each reaction well contained the following: 7 ul cDNA, 10 ul Universal PCR
Master Mix, 1 ul 20XTarget Primers and Probe, 2 ul DEPC-treated water. Real-time
PCR was performed with TaqMan® probes (Applied Biosystems) designed for rat ETa
receptor and ETb receptor. PCR was initiated by a 10 min step at 95°C followed by 45
two-step cycles of 15 s at 95°C and then 1 min at 60°C. The fluorescent signal from the
probe (FAM-labeled reporter dye; NFQ labeled-quencher dye) was measured by the ABI
prism 7900HT Fast Real-Time PCR system. The number of cycles required for the
fluorescence signal from each well to reach a fixed threshold is defined as the cycle
threshold (Ct). The fluorescence signals from 18S mRNA served as controls for the
differences in total cDNA loading in the wells. Levels of target sequence were quantified
by calculating the difference between the Ct for the target sequence and coamplified 18S
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RNA (∆∆Ct). One sample with the highest ∆∆Ct value was chosen as a calibrator and
assigned a Relative Quantification (RQ) value of 1.0. All other samples were quantified
relative to the calibrator.
Determination of ETa and ETb receptor protein
Coronary arterioles (n = 4/rat) were immediately snap frozen and stored at −80°C
until ready for use. After addition of 15 ul lysis buffer, arterioles were solubilized and
protein content was assessed by NanoOrange assay (Molecular Probes). Five μg of
protein from each sample was electrophoresed on 10% SDS-polyacrylamide gels and
transferred to polyvinylidene difluoride (PVDF) membranes. Following blocking (6%
nonfat dry milk), membranes were incubated with primary antibodies overnight at 4 °C
(ETa (1:1000) or ETb (1:1000) (Sigma-Aldrich)). After washing, membranes were
incubated with the appropriate horseradish peroxidase-conjugated species-specific antiIgG (1 h). Peroxidase activity was detected by enhanced chemiluminescence (Super
Signal West Femto, Pierce). Densitometric analysis of immunoblot films was performed
using NIH ImageJ 1.38x Analysis Software (National Institutes of Health, Bethesda,
MD). Equal loading was confirmed by Sypro Ruby staining for total protein.
Solutions and Drugs
Albumin was purchased from USB Chemicals (Cleveland, OH).
chemicals were purchased from Sigma Chemical (St. Louis, MO).
Data Analysis
Data are expressed as means ± standard error.
Spontaneous Tone (%) = [(D M – D T )/D M ] x 100

All other
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where D M is the maximal diameter recorded at 60 cmH 2 O and D T is the steady-state
baseline diameter recorded at the same pressure. Constriction to ET was expressed by
the following equation:
Constriction (%) = [(D b –D s )/ID b ] x 100
where D b is the baseline diameter immediately prior to addition of the first dose of
vasoconstrictor agonist, and D s is the steady state diameter measured after addition of
each dose. Arteriolar distensibility was calculated by the following equation:
Distensibility (% change in arteriolar diameter/mmHg) = [∆ID/(D s x ∆P IL )] x 100
where ∆ID represents the change in internal arteriolar diameter for each incremental
change in intraluminal pressure (∆P IL ), and D s is the steady state diameter measured after
increasing intraluminal pressure.
Concentration-diameter curves were evaluated by repeated measures ANOVA in
order to detect differences within and between factors. Pairwise comparisons were made
by post-hoc analysis (Bonferroni) when a significant main effect was found. One-way
ANOVA was used for comparisons of animal and vessel characteristics. Significance
was set at (P ≤ 0.05).

RESULTS
Animal Characteristics
Old male and female rats had a higher body weight and heart weight than young
male and female rats (Table 3.1). Heart weight to body weight ratio was increased with
age in males, but decreased in females (Table 3.1).
Vessel Characteristics
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Maximal diameter of coronary arterioles was increased in old males compared to
young male (Table 3.1). Spontaneous tone was greater in arterioles from young males
compared to arterioles from young females (Table 3.1). Arterioles from old females
developed greater spontaneous tone after denudation compared to young females (Table
3.1).

BQ-123 did not alter spontaneous tone in any group.

BQ-788 decreased

spontaneous tone only in arterioles from young males (Table 3.1).
Response to ET
Old age altered the vasoconstriction to ET in coronary arterioles from both male
and female rats (Fig 3.1).

As shown previously, ET-induced vasoconstriction was

impaired in arterioles from old males compared to those from young males (Fig 3.1A).
In contrast, age increased vasoconstriction to ET in arterioles from female rats (Fig 3.1B).
In young rats, vasoconstriction to ET did not differ between arterioles from males and
females; however, ET-induced vasoconstriction was greater in arterioles from old female
rats compared to arterioles from old male rats (Fig 3.1). Following denudation, agerelated differences were abolished in coronary arterioles from male rats (Fig 3.2A), but
remained in coronary arterioles from female rats (Fig 3.2B).
Contribution of ETa receptor
There were no age-related differences in ET-induced vasoconstriction in intact
arterioles after pretreatment with BQ-788, an ETb receptor inhibitor, in either males or
females (Fig 3.3). Following denudation, ET-induced vasoconstriction in the presence of
BQ-788 remained greater in arterioles from young males compared to those from old
males (Fig 3.4A).

Vasoconstriction to ET in the presence of BQ-788 in denuded

coronary arterioles from old females was greater than those from young females (Fig
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3.4B). These data indicate that ETa receptor-mediated vasoconstriction is altered with
age in both males and females.
Contribution of ETb receptor
There were no age-related differences in ET-induced vasoconstriction in intact
arterioles after pretreatment with BQ-123, an ETa receptor inhibitor, in either males or
females (Fig 3.3). Likewise, in denuded artetioles from both males and females, agerelated differences to ET-induced vasoconstriction were abolished by pretreatment with
BQ-123 (Fig 3.4). These data indicate that ETb receptor-mediated vasoconstriction is
preserved with age in males and females.
Passive Pressure Response
To determine whether structural changes contributed to age-induced changes in
ET-mediated vasoconstriction, passive distensibility curves were determined in coronary
arterioles from young and old female rats.

There were no age-related differences

between the passive responses to increasing pressure in arterioles from young and old
female rats (Fig 3.5). Previous data demonstrated that age did not alter the passive
pressure-diameter relationship in arterioles from male rats (97).
ETa and ETb receptor mRNA expression
Both ETa and ETb receptor mRNA expression was decreased in arterioles from
old males compared to arterioles from young males (Fig 3.6 A,B).

However, neither

ETa or ETb receptor mRNA expression was altered with age in coronary arterioles from
females (Fig 3.6 C,D).
ETa and ETb receptor protein expression
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ETa receptor protein was decreased in arterioles from old males compared to
arterioles from young males (Fig 3.7A). ETb receptor protein was increased in coronary
arterioles from old males compared to arterioles from young males (Fig 3.7B). There
were no age-related differences in ETa or ETb receptor protein in coronary arterioles
from females (Fig 3.7 C,D).
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Young
Male

Old
Male

Young
Female

Old
Female

330±6

394±5*

205±2

298±3*

(54)

(48)

(35)

(34)

Heart Weight (mg)

1,007±18

1,385±23*

582±9

774±12*

HW/BW (mg/g)

3.06±0.04

3.54±0.08*

2.83±0.03

2.62±0.05*

120±3

131±4*

124±3

126±4

(50)

(54)

(50)

(49)

34±2

29±2

28±2 †

31±3

(9)

(10)

(10)

(8)

32±6

28±6

24±5

40±6*

(6)

(9)

(7)

(11)

33±6

23±4

35±5

29±4

(15)

(15)

(15)

(14)

26±4 ‡

24±4

23±5

24±6

(20)

(19)

(19)

(15)

Animal Characteristics
Body Weight (g)
(n)

Vessel Characteristics
Maximal Diameter (μm)
Spontaneous Tone (%)
Endothelium Intact
Denuded
Post BQ123
Post BQ788

Table 3.1. Animal and vessel characteristics of young and old male and female rats. Values are means ±
SE. * Indicates significant age-effect, † Indicates significant age-matched gender difference, ‡ Indicates
significant treatment effect compared to spontaneous tone (P ≤ 0.05).
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Figure 3.1. Vasoconstriction to ET in coronary arterioles from young and old males (A) and females (B). ET-induced vasoconstriction was decreased with
advancing age in coronary arterioles from males (A), but increased in coronary arterioles from aged females (B). Values are means ± SE. * Indicates significant
age-related difference vs. young control, (P ≤ 0.05).

56

A

100

B

100

Young Male Denuded (n = 7)
Old Male Denuded (n = 9)

80

% Constriction

% Constriction

80

Young Female Denuded (n = 7)
Old Female Denuded (n = 11)

60

40

20

0

*

60

40

20

0

1e-11

1e-10

1e-9

Endothelin [M]

1e-8

1e-11

1e-10

1e-9

1e-8

Endothelin [M]

Figure 3.2. ET-induced vasoconstriction in denuded coronary arterioles from young and old males (A) and females (B). Age-related differences in
vasoconstriction to ET was abolished after denudation in arterioles from males (A), but remained in arterioles from females (B). Values are means ± SE. *
Indicates significant age-related difference vs. young control, (P ≤ 0.05).
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Figure 3.3. Vasoconstriction to ET after pretreatment with BQ123 (1x10-6 M), an ETa receptor inhibitor, or BQ788 (3x10-8 M), an ETb receptor inhibitor, in
coronary arterioles from young and old males (A) and females (B). No age-related differences were found in ET-induced vasoconstriction in coronary arterioles
after inhibition of ETa or ETb receptors in either sex. Values are means ± SE.
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Figure 3.4. ET-induced vasoconstriction in denuded coronary arterioles after inhibition of ETa (BQ123 1x10-6 M) or ETb (BQ788 3x10-8 M) receptors in young
and old males (A) and females (B). No age-related differences were found in ETb-mediated vasoconstriction in denuded coronary arterioles from either sex.
Pretreatment with BQ788 (ETb inhibitor) revealed age-related differences in the vasoconstriction to ET in males (A) and females (B). Values are means ± SE. *
Indicates significant age-related difference vs. young control, (P ≤ 0.05).
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Figure 3.5. Passive distensibility curves in coronary arterioles from young and old females. There were
no age-associated differences in the passive distensibility to increases in intraluminal pressure. Values are
means ± SE.
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Figure 3.6. Both ETa and ETb mRNA expression was decreased in old males when compared to young
males (A,B). No age-related differences were found in ETa or ETb mRNA expression from females (C,D)
(n ≥ 8 per group). Values are means ± SE. * Indicates significant age-related difference vs. young control,
(P ≤ 0.05).
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Figure 3.7. Advancing age in males caused a decrease in ETa protein expression (A), but an increase in
ETb protein expression (B) in coronary arterioles (Young male, n = 4; Old male, n = 5). No age-related
differences were found in ETa or ETb protein expression in coronary arterioles from females (C,D) (n = 8
per female group). Representative blots of either ETa or ETb receptor protein (~45 kd) are shown below
graphs. Values are means ± SE. * Indicates significant age-related difference vs. young control, (P ≤ 0.05).
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DISCUSSION
Coronary blood flow is meticulously regulated by the release of a combination of
relaxing and constricting factors that help alter blood flow in response to changes in
metabolism. ET functions as a modulator of basal vascular tone in the heart and
contributes to coronary blood flow during periods of low metabolism (71). The longlasting vasoconstriction caused by ET can redirect coronary blood flow in order to
promote subendocardial perfusion and has been proposed to prevent excessive back flow
from the coronary circulation (71). The major finding from this study is that ET-induced
vasoconstriction is differentially altered with age in coronary resistance arterioles from
male and female rats (Fig 3.1). In coronary arterioles from males, the age-related
decrement in ET-induced vasoconstriction is accompanied by a decrease in the
expression of ETa receptor mRNA and protein (Fig 3.6 A, 3.7 A). In coronary arterioles
from females, the increase in responsiveness to ET that occurs with advancing age is not
associated with changes in expression of either ETa or ETb.
Considerable heterogeneity exists in the age-related response to ET in the
vasculature, and depends on which specific vascular bed is being investigated. For
example, a decrease (25), no change (53), or increase (26) in the vasoconstriction to ET
with advancing age has been shown in mesenteric arteries, aorta, and gastrocnemius
arterioles, respectively. Thus, vasoconstriction to ET varies between vessels from
different vascular beds and between conduit and resistance vessels. This laboratory has
previously demonstrated a decrease in vasoconstriction to ET with advancing age in
coronary arterioles from male rats (97). In contrast, in large coronary arteries from aged
male rats, ET-mediated vasoconstriction is increased compared to arteries from young
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rats (50, 113). On the other hand, whole-heart evaluations of ET-induced
vasoconstriction have shown no age-related changes (34), which suggests an age-related
impairment specific to the microcirculation in male hearts. This decrement in
vasoconstriction to ET may contribute to altered blood flow in the hearts of senescent
male rats (42, 115). Thus, the results show that the age-related impairment of ETinduced vasoconstriction in males is specific to coronary arterioles and does not coincide
with age-related alterations in vasoconstriction to ET in larger coronary arteries from
male rats.
In contrast to the male literature, there are extremely few studies regarding the
age-related response to ET in any vascular bed in females. Apparently, this is the first
study to investigate the effects of age on ET-mediated vasoconstriction in the coronary
resistance arterioles of females. In contrast to the present finding of increased ETmediated vasoconstriction of arterioles from aged females, large epicardial arteries
exhibit a decrease in maximal constriction to ET in senescent females, but this decrease
in ET-mediated constriction was associated with an increase in both Big ET and
functional endothelin converting enzyme (ECE) activity, two upstream regulators of
endothelin production (7). In addition, age-related increases in vasoconstrictor responses
to 5-HT in mesenteric arteries (109) and KCl and norepinephrine (NE) in aortas (7) from
females have been reported, along with augmented plasma ET-1 levels in senescent
females (7, 11, 122). This suggests that females exhibit an enhanced vasoconstrictor
profile along with an increase in ET levels as age progresses, and this may contribute to
the heightened ET-induced vasoconstriction in coronary arterioles shown in the present
study.
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Endothelin mediates its effects via two distinct G-coupled protein receptor
subtypes. ETa receptors are the major subtype of receptors involved in the
vasoconstrictor response to ET and are localized on the vascular smooth muscle (VSM)
cell (66). ETb receptors located on the endothelial cell mediate vasodilation through the
release of relaxing factors, but can exert vasoconstriction through ETb receptors located
on the smooth muscle (66). Therefore, the net effect of endothelin depends on the
relative distribution and density of each specific subtype of receptor. In the current study,
in arterioles from both males and females, age-related differences in responses to ET
remained after denuding and pretreatment with BQ-788, indicating ETa-mediated
vasoconstriction is altered with advancing age (Fig 3.4). ETa mRNA and protein was
decreased with old age in coronary arterioles from males and corroborates the decrement
in ETa-induced vasoconstriction. In females, ETa mRNA and protein were not changed
in coronary arterioles with age, suggesting that the age-related increase in ETa-mediated
constriction occurs as a result of alterations in the signaling mechanisms in the VSM
downstream of the receptor. Aberrant ETa-mediated constrictor responses with
advancing age have been shown in coronary arteries (51) and skeletal muscle arterioles
(26) in male rats; however, unlike the reduction of constriction to ET that occurs in
coronary arterioles in the present study, ET-mediated constriction increases in these
vascular beds with advancing age.
The ETb receptor on the endothelium is distinctive from the ET receptors on the
smooth muscle due to the signaled release of relaxing factors, in particular NO (114).
The endothelial ETb receptor has also been shown to modulate the vasoconstrictor effects
of ET bound to ETa or ETb receptors on the vascular smooth muscle (114). In the present
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study, ETb receptor protein expression was increased with old age in males (Fig 3.7 B).
However, this receptor increase cannot be ascribed to either the endothelium or VSM
location because the increase in ETb receptor protein in coronary arterioles from old
males may occur in both the endothelium and VSM. Seo and Luscher (94) found that
stimulation of ETb receptors on the endothelium of renal arteries release more NO with
advancing age in male rats; therefore, the decreased vasoconstriction to ET exhibited by
aged males in the present study could be due to an increase in ETb receptor-mediated
vasodilation in the endothelium. An increase in eNOS mRNA expression in coronary
arterioles shown previously (97) supports the greater ETb-receptor mediated vasodilation
in aged males, perhaps due to enhanced nitric oxide (NO) production from the
endothelium. This is further supported by the finding that vasoconstriction to ET after
denudation was increased in coronary arterioles from old versus young males, thereby
abolishing age-related differences (Fig 2A). In addition, the loss of age-related
differences in intact coronary arterioles in males after treatment with BQ788 suggests that
the endothelial ETb receptor exerts a greater vasodilatory stimulus in coronary arterioles
from aged males compared to those from young males (Fig 3.1A and Fig 3.3A). The
possible increase in ETb receptor protein on the VSM in arterioles from old males may
also contribute to the loss of age-related differences in coronary arterioles after
denudation in males. In the current study, ET-induced vasoconstriction increased in
coronary arterioles from both young and old males after denudation (Fig 3.1A and Fig
3.2A), but this increase was greater in arterioles from old males. These data indicate that
the impaired vasoconstriction to ET with advancing age in coronary arterioles from males
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may be attributed to age-related modifications of the endothelium and an increase in ETb
receptor number on the endothelium of coronary arterioles in male rats.
Since age-related differences in ET-mediated vasoconstriction remained after
denudation in females, endothelium-independent mechanisms, such as smooth muscle
mechanics and Ca2+ handling should be considered. Large arteries from female rats
exhibit lower b-myosin and higher levels of sarcoplasmic reticulum Ca2+-ATPase
expression compared to those from male rats (119). Lopes et al. (63) found that aged
female rats exhibited an increase in colon smooth muscle contraction and suggested this
might be due to increases in Ca2+ stores. Indeed, Ca-induced Ca-release is impaired in
mesenteric resistance arteries from aged rats leading to an increase in stored Ca2+ content
(89). In aggregate, these studies suggest that alterations in Ca2+ handling that occur with
age could lead to heightened vasoconstriction to ET as seen in coronary arterioles from
aged female rats.
In addition to Ca2+ alterations, NO feedback on ET signaling could also explain
the divergent response to ET observed in aged males and females. In 1990, Boulanger
and Luscher (9) first demonstrated that NO inhibits formation of ET in the aorta and
suggested that an impaired release of NO from the vasculature may lead to an
exaggerated ET production. In addition, NO has been shown to actively displace ET
from its receptor binding site on vascular smooth muscle (33) and can directly bind to
thiol groups on the ET receptor causing reduction of the thiol groups and the production
of active s-nitrosothiols, a stable NO metabolite that can contribute to vasodilation (17,
101). Unpublished data from this laboratory has shown a decrement in NO-mediated
vasodilation in coronary arterioles from aged females, while males exhibit an increase in
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eNOS mRNA with advancing age (97). Perhaps these opposing gender-related NO
regulatory mechanisms could explain why age-associated adaptations of ET signaling are
directionally opposite.
To date, there are no studies which have investigated structural adaptations in
coronary arterioles of aged females. Although the present results show passive
distensibility curves of coronary arterioles from young and old female rats were not
significantly different (Fig 3.5), remodeling in the heart with advancing age may
influence vasoreactivity of the arterial system. In humans, older women exhibit an
increased augmentation index (i.e. an accepted measure of the pulsatile vascular load due
to arterial stiffness and wave reflection) in carotid arteries compared to age-matched
males (44). Also, a study of over 600 subjects found that arterial compliance is greater in
large arteries from younger females, then diminished at the time of menopause (59).
Likewise, the removal of ovarian hormones has been shown to cause an increase in left
ventricle remodeling, specifically an increase in beta-myosin heavy chain isoform and
collagen I/III ratio, in middle-aged females (128). However, estrogen-replacement could
attenuate this remodeling (128) and favorably enhance arteriolar distensibility (21). In
contrast to males, the decrease in HW/BW ratio with advancing age in females seen in
the present study indicates that age-related cardiac hypertrophy does not parallel the
increase in body weight exhibited throughout the female life span (Table 3.1). In total,
these data indicate that the loss of estrogen with advancing age may contribute to overall
cardiac remodeling and may influence the augmented response to ET in aged females.
In addition to the potential VSM effects, modulation of ET-induced constriction
by endothelial factors clearly differs in arterioles from males compared to arterioles from
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females. A significant endothelial-derived constrictor influence appears to contribute to
the ET-mediated vasoconstriction in coronary arterioles from both young and old
females, as exhibited by a decrease in constriction induced by denudation in arterioles
from both young and old females (Fig 3.1B and Fig 3.2B). In contrast, ET-induced
vasoconstriction in the presence of BQ788 in intact coronary arterioles increased after
denudation from old, but not young, females (Fig 3.3B and Fig 3.4B), suggesting that an
endothelial dilator modulates constriction to ET in arterioles from old females. This is
similar to coronary arterioles from males, in which age increases an ET-sensitive
vasodilatory influence in the endothelium. In contrast to arterioles from males, the
presence of an ET-sensitive endothelial vasoconstrictor appears to be unique to coronary
arterioles from females. In all, age may alter vasoconstriction to ET in arterioles from
females through changes in a combination of endothelial constrictor and dilator
influences.
ET has been shown to be increased in chronic diseases such as congestive heart
failure (68) myocardial infarction (74) and hypertension (13). Because the risk for these
diseases increases with advancing age, and because these diseases are accompanied by
coronary vascular dysfunction, it is imperative to determine how advancing age alters
vasoreactive responses to ET of the coronary resistance vasculature. This study provides
insight into the different mechanisms by which vasoconstriction to ET occurs in coronary
arterioles from males and females and provides targets for future experimental
approaches aimed at the endothelin-1 system.
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CHAPTER IV
SUMMARY

These two studies determined that in coronary resistance arterioles, vasoreactivity
to dilating and contricting factors are altered with age in both male and female Fischer
344 rats. The first paper demonstrated that endothelium-dependent NO-mediated
signaling was decreased with advancing age in coronary arterioles from females and
contributes to the decrement in flow-induced vasodilation with age. This age-related
impairment can be restored, however, as ovariectomy plus estrogen-replacement
enhanced vasodilation to flow in coronary arterioles from senescent females compared to
arterioles from old OVX and control females. This improvement in flow-induced
vasodilation after estrogen-replacement in arterioles from aged females correlates to
increases in phosphorylated and total eNOS protein expression.
The second paper showed that advancing age dichotomously affects
vasoconstriction to endothelin in coronary arterioles from males and females. Coronary
arterioles from males exhibit an age-related decline in vasoconstriction to ET which is
primarily mediated through an age-related decline in ETa receptor mRNA and protein
expression. In contrast, coronary arterioles from females increase ET-induced
vasoconstriction with advancing age, but this is not due to age-related alterations in ETa
or ETb receptor mRNA or protein expression. Instead, structural adaptations in the heart
due to the decline in circulating estrogen and age-related alterations in VSM in coronary
arterioles from senescent females may contribute to the increase in ET-induced
vasoconstriction.
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The implications of these findings are multifold for the field of aging and the
microcirculation. 1) Regardless of gender, vasodilation to flow-induced dilation is
impaired in coronary arterioles with advancing age. 2) Advancing age differentially
affects the vasoconstrictor responses to endothelin in coronary arterioles according to
gender. 3) Perhaps most importantly is that estrogen-replacement after ovariectomy in
the aged female rat improves endothelium-dependent vasodilation in coronary arterioles
to levels seen in arterioles from young females. This suggests that the methodology and
results of the WHI and HERS studies need to be revisited because the present data
indicate a positive relationship with estrogen-replacement in the aged coronary
microcirculation. It is possible that by utilizing a more optimized animal model, as in the
first paper, the effects of estrogen on other vascular beds can be more accurately gauged
and the combined effect of estrogen and progesterone on the risk for cardiovascular
events can be investigated.
Since a release of both relaxing and constricting factors influence coronary blood
flow, altered vasoreactivity with age and/or gender can significantly impede distribution
and supply of blood to the subendocardium. These data suggest that age-related changes
in the vasoreactivity of coronary arterioles from males and females may contribute to the
increase in risk for heart failure and declining coronary flow reserve that occurs in
senescent animals and humans (19, 42). In addition, this research has elucidated the
basic mechanisms by which primary aging occurs and those which are affected by
reproductive senescence. Therefore, not only is it important to consider age in future
therapeutic approaches for CVD, but gender as well.
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